EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections

Anton Petcherski iD, Brett M Tingley iD, Andrew Martin iD, Sarah Adams iD, Alexandra J Brownstein iD, Ross A Steinberg iD, Byourak Shabane iD, Jennifer Ngo iD, Corey Osto iD, Gustavo Garcia iD, Michaela Veliova iD, Vaithilingaraja Arumugaswami iD und 3 weitere

Life Science Alliance · 2025-04 · 8 (4) · e202403182

DOI: 10.26508/lsa.202403182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 03.02.2025. Verfasst von Anton Petcherski und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Lysosomes, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCLA COVID-19 Emergency Response, BU Nano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100–150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2LysosomesCOVID-19 Drug TreatmentNanoparticlesNanoparticle Drug Delivery SystemAnimalsHumansMiceCOVID-19EndosomesDrug Delivery SystemsEndocytosisHydroxychloroquineLung

Substanzen

Antiviral AgentsHydroxychloroquineNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Department of Biomedical Engineering, Boston University, Boston, MA, USA.
  • Molecular Cellular Integrative Physiology, University of California Los Angeles, Los Angeles, CA, USA.
  • Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Department of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA oshirihai@mednet.ucla.edu.
  • Department of Biomedical Engineering, Boston University, Boston, MA, USA mgrin@bu.edu.

ORCID-Profile: Anton Petcherski, Brett M Tingley, Andrew Martin, Sarah Adams, Alexandra J Brownstein, Ross A Steinberg, Byourak Shabane, Jennifer Ngo, Corey Osto, Gustavo Garcia, Michaela Veliova, Vaithilingaraja Arumugaswami, Aaron H Colby, Orian S Shirihai, Mark W Grinstaff

Förderung

  • UCLA COVID-19 Emergency Response
  • BU Nano

Zitieren

APA

Petcherski, A., Tingley, B. M., Martin, A., Adams, S., Brownstein, A. J., Steinberg, R. A., Shabane, B., Ngo, J., Osto, C., Garcia, G., Veliova, M., Arumugaswami, V., Colby, A. H., Shirihai, O. S., & Grinstaff, M. W. (2025). Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections. Life Science Alliance, 8(4), e202403182. https://doi.org/10.26508/lsa.202403182

Vancouver

Petcherski A, Tingley BM, Martin A, Adams S, Brownstein AJ, Steinberg RA, et al. Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections. Life Science Alliance. 2025;8(4):e202403182. doi:10.26508/lsa.202403182

BibTeX
@article{Petcherski2025,
  author = {Petcherski, Anton and Tingley, Brett M and Martin, Andrew and Adams, Sarah and Brownstein, Alexandra J and Steinberg, Ross A and Shabane, Byourak and Ngo, Jennifer and Osto, Corey and Garcia, Gustavo and Veliova, Michaela and Arumugaswami, Vaithilingaraja and Colby, Aaron H and Shirihai, Orian S and Grinstaff, Mark W},
  title = {Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections},
  journal = {Life Science Alliance},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {e202403182},
  doi = {10.26508/lsa.202403182}
}
Kostenlos starten →